SI
SI
discoversearch

Biotech / Medical
ProMetic Life Sciences
An SI Board Since April 2016
Posts SubjectMarks Bans Symbol
79 8 0 PLI
Emcee:  axial Type:  Moderated
PROMETIC LIFE SCIENCES — prometic.com

ProMetic is a biopharmaceutical corporation with globally recognized expertise in bioseparation and uses its own affinity technology for the development of best in class plasma-derived therapeutics. ProMetic is also active in developing its own novel small molecule therapeutics products. Headquartered in Laval, Canada, ProMetic has a global presence through its various sites in the UK and USA, providing both manufacturing and R&D capability. These strategic locations facilitate ProMetic’s growth globally and supports all business activity in American, European and Asian markets. ProMetic is publicly traded on TSX (Symbol: PLI) and OTCQX (Symbol: PFSCF).

ProMetic has developed core competencies in strategic fields, including:
  • Purification of biologics
  • Drug development
  • Proteomics
  • Elimination of pathogens
The business is now focused on developing its range of therapeutics from both its plasma-derived and small-molecule platform.
___________________________________________

WELCOME! —This is a moderated board. No spam, ad hominem attacks or flaming. One warning. Next time you're out, with your posts deleted.
___________________________________________
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
79There's no obvious sign of trouble ahead, but the stock always seems to holdaxial-last Friday
78Sounds like we are on track for Q4!Leo Fisher-last Friday
77PROMETIC ENTERS INTO BINDING AGREEMENT TO SECURE $25 MILLION FOLLOW-ON FINANCINaxial-last Friday
76PROMETIC TO REPORT ITS FOURTH QUARTER AND YEAR-END 2016 FINANCIAL RESULTS AND HOaxial-last Thursday
75Trump chooses Gottlieb to run FDA; Pharma breathes sigh of relief 'U.S. Praxial-March 11
74Excerpt : 2017 RBC Capital Markets’ Healthcare Conference Unconfirmed — no linkaxial-March 6
73Prometic video — Progress update to March 2017 here. Jimaxial1March 5
72US FDA GRANTS ORPHAN DRUG DESIGNATION TO PROMETIC’S PBI-4050 DRUG FOR THE TREATMaxial1March 3
71Interesting article posted today on PLI website: -Early evidence of efficacy ofLeo Fisher1February 22
70NASDAQ and PROMETIC The following is a recent email sent to a Prometic investoraxial-February 20
69Pediatric Priority Review Voucher — Regulatory Explainer: Everything You Need taxial-February 15
682016 article — paid plasma collection in Canada Blood money: Legislated out of axial-February 15
67CALIFORNIA CAPITAL EQUITY, LLC ACQUIRES 44 MILLION PROMETIC SHARES THROUGH THE Eaxial-February 6
66Hi Leo - "Hematech most likely did not meet the strict manufacturing stanaxial-February 1
65EUROPEAN COMMISSION GRANTS ORPHAN DRUG DESIGNATION TO PROMETIC’S PBI-4050 DRUG Faxial-February 1
64PROMETIC’S PBI-4050 RECEIVES PROMISING INNOVATIVE MEDICINE DESIGNATION FROM THE axial-February 1
63PROMETIC REACQUIRES PLASMINOGEN RIGHTS FROM HEMATECH Regains 100% ownership of axial-February 1
62Rick, it's an interesting stock -- to trade, or as a buy and hold. Good to haxial-February 1
61Peanuts to reacquire rights, modest royalty going forward. -Hematech most likelyLeo Fisher-January 10
60Jim... thanks for bringing this company to our attention. I position trade, scaram(o)uche-January 10
59Today's move is wonderful, but it again leaves me with the feeling that Iscaram(o)uche-January 5
58I get the high market cap / hemorrhaging of cash, but that's not unusual forLeo Fisher-January 5
57there is also this..... ncbi.nlm.nih.govscaram(o)uche-January 4
56from Tefs et al, 2003..... the K19E mutation in the plasminogen gene is a comscaram(o)uche-January 4
55Well.... fairly large market cap, no cash. Cash runway will last until imporscaram(o)uche-January 4
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.